Constraint-induced movement therapy (CIMT) was developed to overcome upper limb impairments after stroke and is the most investigated intervention for treatment of patients.
INTRODUCTION
review and subsequent meta-analysis of trials applying original CIMT or mCIMT is needed. Panel 7.1 summarizes definitions and description of rehabilitation terminology for (m)CIMT in this review.
EFFECTS OF CIMT
CIMT has been investigated in 51 RCTs, 23, [28] [29] [30] [31] and in 1784 adult patients with stroke, but only 15 trials included patients within the first 3 months after stroke. 34, 45, 47, 49, 50, 52, 53, 56, 59, 66, 67, 69, 76, 78, 82 Panel 7.2 gives a quick overview of the search strategy and selection criteria for our systematic review, while the Supplementary Web Appendix provides further details about the search strategy, methods, and flow chart.
ORIGINAL CIMT
Original CIMT, although seen as the gold standard, has been investigated in only one RCT [28] [29] [30] that included patients who had had a stroke more than 3 months previous to enrolment in the trial (Supplementary Web Appendix). After CIMT, significant positive medium to large effect sizes were reported for arm-hand activities, self-reported amount of arm-hand use in daily life, and selfreported quality of arm-hand movement in daily life ( Physiotherapy Evidence Database (PEDro). We searched all databases from inception to September 24, 2013 . The indexing terms and free-text terms with synonyms and related terms in the title or abstract used were "stroke, " and "physical restraint" or "constraint-induced movement therapy" or "forced use" or "immobilization" or "learned nonuse, " and "randomized controlled trial" or "reviews" (Supplementary Web Appendix). We included articles that were of adult stroke patients; that used a randomised controlled trial design including those with a two-group parallel, multiarm parallel, crossover, cluster, or factorial design; in which the experimental intervention conformed to the definitions of original constraint-induced movement therapy (CIMT), modified CIMT (mCIMT), or forced use; in which the comparator was usual care, another intervention, the same intervention with a different dose, or no intervention; and in which outcomes were measured after intervention or at follow-up.
Panel 7.1 Definitions and description of rehabilitation terms
Original constraint-induced movement therapy (CIMT) -A form of rehabilitation therapy that consists of three components: immobilization of the non-paretic arm with a padded mitt for 90% of the waking hours; task-oriented training with a high number of repetitions for about 6 hours a day during 10 consecutive working days; and, behavioral strategies to improve both compliance and transfer of the practiced activities from the clinical setting to the patient's home environment.
22,127
Modified CIMT (mCIMT) -This therapy does not include the three components of original CIMT, but is restricted to repetitive, task-specific training of the paretic arm, including shaping procedures, applied in a different dose, combined with constraining of the non-affected hand by a padded mitt, glove, or splint.
Forced use therapy -An intervention that is limited to immobilization of the nonparetic arm to increase the amount of use of the paretic limb. No formal behavioral training (shaping) is specified in the treatment protocol.
Intensity of original and modified CIMT -Number of hours spent in supervised exercise therapy.
128,129
Treatment contrast -Time spent on exercise therapy for the experimental group minus that for the control group. 
FORCED USE THERAPY

EFFECTS OF TYPE, DOSE, AND TIMING OF CIMT AFTER STROKE AND SMALL STUDY EFFECTS
Sensitivity analysis showed no significant differences in effect sizes between original CIMT and mCIMT, dose of (m)CIMT (additional time spent in exercise therapy between 5 hours 51 and 60 hours 28, 36, 38, 40, 42 [mean 46.8 hours]), and timing of (m)CIMT when comparing trials that started within or after the first 3 months from when a patient had a stroke. Aditionally, robust effects for (m)CIMT do not seem to be affected by small-study effects or publication bias, or moderated by risk of bias (Supplementary Web Appendix). Although we noted no evidence for small-study effects, a meta-regression of mCIMT trials showed that methodological quality was a significant effect modifier for motor function after intervention and self-reported use in daily life at follow-up.
WHAT DRIVES IMPROVEMENTS BY CIMT AND MCIMT?
The underlying mechanisms that drive improvement by (m)CIMT are still poorly understood. First, we expected that intensity of task-specific practices (expressed as differences in treatment duration)
would be a significant moderator of CIMT. However, our meta-analysis showed no evidence that the type of CIMT or differences in treatment times between groups within a trial -which amounted to a mean of 47 hours -had an effect. 94, 96, 97 which are also restricted to the first 3 months after stroke. 98, 99 Our meta-analysis further suggests that the effects of mCIMT on motor function of the arm such as Fugl-meyer Assessment arm scores, is mainly restricted to trials that started within 3 months after stroke (Figure 7 .4; Supplementary Web Appendix). 34, 45, 49, 50, 82 This finding is in agreement with the increased evidence from animal studies in which the first weeks after stroke onset are characterized by increased levels of homeostatic neuroplasticity.
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WHO SHOULD BE SELECTED FOR CIMT?
An important inclusion criterion for the original CIMT trial was that patients showed some voluntary extension at the wrist and some minimal extension at the metacarpophalangeal and interphalangeal joints at baseline. 28 Within this selection criterion higher-functioning participants who show at least 20° of wrist extension and 10° of active extension of each metacarpophalangeal and interphalangeal joint for all digits can be distinguished from lower-functioning participants who show at least 10° of active wrist extension, 10° of thumb abduction or extension, and 10° of extension in a minimum of two additional digits. Preferably, these movements had to be repeated three times in 1 minute. 101 Although severity of stroke was not formally tested in the present review, the ability to extend one or more fingers of the paretic side seems to be 'natural' because active repetition of movements and activities is not possible when there is no function. Findings from TMS 86 and diffusion tensor imaging 102,103 studies have shown that voluntary wrist and, particularly, finger extension are highly associated with the integrity of the corticospinal tract system. This type of motor function is the strongest clinical predictor for the return of some dexterity in the first days after stroke. [103] [104] [105] [106] Fritz and colleagues 107 showed in 55 patients with chronic stroke that initial ability of finger extension was the only significant predictor of outcomes for the WMFT after applying original CIMT. The selection of patients with some extension of wrist and fingers should be regarded as a key factor determining the potential for change 103, 105 and reversal of learned non-use by CIMT after stroke. 107 Additionally, because of concerns about the safety of the restraint by a sling or splint applied in the original form of CIMT, 36 which might prevent adequate protective reactions to control standing balance, the restraint was replaced by a padded mitt, 108 and patients should be able to stand for at least 2 minutes with or without support. 16 More general criteria were a Mini-Mental State Examination (MMSE) score of 24 or more, no major medical problems that could interfere with participation, no history of disabling stroke, no excessive pain or spasticity in the paretic extremity, enough stamina to participate, and age older than 18 years. 16 Collectively, these criteria suggest that (m)CIMT is best restricted to patients with a mild to moderate paresis with a predominantly favorable chance for for dexterity early after stroke. About 10% (range from 3% 53 to 90% 59 ) of initially screened patients of included trials in this review were eligible for (m)CIMT.
SYNTHESIS OF EVIDENCE ABOUT CIMT
mCIMT (44 trials in dexterity is clinically meaningful. 110 This finding further emphasizes that the minimal clinically important difference of used upper extremity measures such as ARAT and WMFT are not only context specific but also dynamic in time. 109 With the exception of muscle tone and basic activities of daily living, the significantly positive effects of mCIMT (i.e. motor function of the paretic arm, arm-hand activities, amount of arm-hand use in daily life, and quality of arm-hand use in daily life) were sustained in the long term, even though the magnitude of the summary effect sizes decreased at follow up. Aditionally, original CIMT had benefits for long term health-related quality of life.
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Our analysis suggests that (m)CIMT has no significant effects on grip strength, sensibility, pain, or health-related quality of life after intervention (Figure 7.4) . However, the statistical power underpinning the evidence was limited by the insufficient number of patients in (m)CIMT trials using these outcomes.
Analysis of RCTs in which the only difference between the experimental and control groups was wearing a mitt on the less affected arm without a structured exercise program (i.e. forced use), showed no benefit. This finding suggests that procedures involving shaping, repetitive exercises, and instructions for behavioural change are the most important components of (m)CIMT. Despite the large number of trials identified, sensitivity analyses showed no significant differences between types of CIMT regimen, timing of (m)CIMT after stroke, or treatment contrast between experimental and control groups. , activities (mid grey), and participation (dark grey). , beneficial or likely to be beneficial based on significant positive summary effect sizes; x, uncertain benefit based on non-significant summary effect sizes; ?, unknown effect based on the inability to statistically pool data of RCTs. ADL, Activities of Daily Living; AOU, Self-reported Amount of Arm-hand Use in Daily Life; CIMT, Constraint-Induced Movement Therapy; QoL, Quality of Life; QOM, Self-reported Quality of Arm-hand Movement in Daily Life. * only beneficial or likely to be beneficial within the first 3 months after stroke.
Outcome
Original CIMT Forced use
Motor function arm ? ?
Grip strength Aditionally, CIMT has greater effects on motor function only when applied in the earlier stages after stroke, in which it is assumed that restitution of neurological functions is still possible; however, when applied in later phases, CIMT solely affects arm-hand activities by learning to use adaptation strategies (i.e. compensation) to improve upper limb performance in activities of daily living.
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LIMITATIONS OF OUR ANALYSIS
Our review has some limitations. Second, although we did not detect common threats to meta-analyses such as small-study effects or publication bias. 112 However, we might have missed small negative trials. We synthesized only aggregate study level data obtained from cited studies of sufficient methodological quality (i.e.
Physiotherapy Evidence Database score of >4 out of 10 points). Including the five trials with moderate methodological quality would not have significantly affected the overall medium-sized effects and conclusions in this review. Unfortunately, we were unable to perform meta-analysis of individual patient data. 113 As a result, we could not investigate possible effect modifiers such as arm dominance, and the effect of cognitive limitations, such as dyspraxia, age, or type of stroke.
To investigate long-term effects, we pooled data from trials with different follow-up intervals.
Furthermore, our meta-analyses of measures such as grip strength and health-related quality of life were underpowered, so the effect of (m)CIMT on these outcomes is unclear. Our sensitivity analyses should be interpreted with caution because of uneven distribution across subgroups, and in some cases inclusion of only one trial in a subgroup; these analyses should therefore mainly be seen as indications. 114 Analyses of the statistical power of pooled trials showed that about half of the analyses for (m)CIMT and forced use after intervention and in the longer term were sufficiently powered ( Figures 7.2 
FUTURE DIRECTIONS
Our review shows that only 15 out of the 51 trials provided mCIMT within the first weeks after stroke, whereas all these 51 RCTs were small, phase II trials. More mCIMT trials are needed that preferably start within the first days after stroke and use different doses of upper limb training. Evidence from animal studies shows that the brain has increased neuroplasticity in the early phases after stroke, which suggests that normalization of motor control by true neurological recovery could be maximized within this time. 92, 93, 100 Several animal studies 100, [115] [116] [117] suggest that (m)CIMT in the first weeks after stroke may enhance upregulation of growth promoting factors such as protein 43, synaptophysin, and other brain derived neurotrophic factors. 117 Additionally, Zhao and colleagues 117 showed that application of (m)CIMT from weeks 1 to 3 after stroke significantly suppressed the upregulation of growth inhibiting factors such as Nogo-A, Nogo receptors, and RhoA expressed in the peri-infarct cortex in Wistar rats. In these animals, mCIMT resulted in significant structural post-synaptic plastic changes in the denervated cervical spinal cord. 117 Application of mCIMT for 4 weeks directly after stroke caused reorganization of the somatosensory cortex and its neural network. 118 An emerging question is whether the structural plasticity introduced by early applied mCIMT also leads to true neurological repair beyond the existing mechanisms of spontaneous neurological recovery in the first phase after stroke. 92 The restricted time for neural mechanisms that are assumed to play a part in the non-linear pattern of spontaneous neurological recovery of body functions (or reduction in impairments) might emphasize the need for more RCTs with intensive serial assessments early after stroke. To improve knowledge about skill acquisition by mCIMT, improvements in repeated assessments should be associated with serial measures of kinematics, biomechanics, and non-invasive neuroimaging techniques after stroke. 2, 92 Investigations are needed about assumptions of learned misuse when patients learn to use their end-effectors in a different adaptive way to normalize motor control early after stroke. 119 Such research should objectively and intensively monitor the quality of motor control in terms of temporalspatial activation patterns of the upper limb and trunk using three-dimensional kinematics and electromyography-controlled measures, in addition to clinical outcomes. 92 This approach would allow investigation of the adaptive changes in the unaffected parts (or: end-effectors) of the paretic arm and trunk during stroke recovery. 94 Coordination measures should be related to neuronal correlates to allow appropriate interpretation of changes in neuroplasticity noted in animal studies. 92, 120, 121 Additional research is also needed to investigate possible detrimental effects of very high doses of early applied (m)CIMT (i.e. >3 hours) within this time of increased homeostatic neuroplasticity, as suggested by some studies in animals [122] [123] [124] and in patients with stroke. 53 However, a recent meta-analysis 121 of eight animal trials showed no significant inverse dose-response relationship of mCIMT on infarct volume (-3%, 95% CI, -15-9; p=0.63). This finding not only further emphasizes that animal models might help to efficiently explore the biological basis of rehabilitation interventions, but also questions its generalizability to humans. 121 No identified trials reported an effect of phenotypic factors such as sex, age or type of stroke, on the effects of (m)CIMT on outcome after stroke. Investigators of a trial claimed large effects for patients with chronic stroke with sensory deficits and neglect. 37 The relation between individual patient characteristics and the effects of (m)CIMT needs further meta-analysis of individual patient data to identify possible effect modification by patients' phenotypes. 113 Most mCIMT trials do not have a transparent treatment protocol with regard to content, timing after stroke, and doses of therapy. Fortunately, investigators are now publishing their treatment protocols more often in journals. Additionally, consensus is needed on the content and timing of tests applied to assess (m)CIMT. 2 Final, barriers to implementation (m)CIMT and factors that might enhance real-world use of the upper paretic limb need further investigation. 23 In view of the scarce health-care resources in most countries and increasing numbers of stroke survivors, the cost-effectiveness of (m)CIMT compared to usual care needs to be assessed. 16 Additions to therapy time will result in a concomitant increase in health-care costs; however, effective therapy could reduce rates of readmission to hospitals and admission to long-term care institutions. 125 Furthermore, innovative, adaptive forms of (m)CIMT, such as group sessions to reduce the staff-to-patient ratio and costs, self-training mCIMT programs, 126 caregiver-support, and supervised practice by e-health support and telerehabilitation services, need to be investigated and compared with the usual face-to-face (m)CIMT for any cost-benefit. 
